Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Positive early trial for Vertex anticancer drug
Vertex expects to recognize revenue of approximately $7 million of the $19.5 million in milestone payments in the fourth quarter of 2005, and the balance in 2006. In
Vertex expects to recognize revenue of approximately $7 million of the $19.5 million in milestone payments in the fourth quarter of 2005, and the balance in 2006. In
The first is a follow-on study of TRX4 in subjects with type 1 diabetes. Previous phase I studies have shown TRX4 can preserve the function of insulin-producing beta
The study will look at the effects of ALN-RSV01 in healthy volunteers in two separate phase I trials. The first trial underway in Europe and is expected to
According to Stem Cell Therapeutics (SCT), analysis and reporting of the phase I trial is anticipated within the first quarter of 2006. The study is expected to characterize
Under the agreement, which is Xencor’s fifth for this technology in the last year, MedImmune will be able to use Xencor’s XmAb proprietary engineered Fc domains to enhance
The US biotech giant has agreed to pay Galapagos in excess of $30 million, should all clinical and commercial events currently programmed be achieved. The collaboration covers computational
The global phase III study has enrolled13,800 patients to help evaluate Angiomax (bivalirudin) as a replacement to the commonly used anticoagulant heparin in patients with acute coronary syndromes.
The Potelligent technology will be used in researching and developing select MedImmune antibodies for potential therapeutic applications that require enhancement of antibody- dependent cellular cytotoxicity (ADCC). Under the
Using AmerisourceBergen and Allscripts solutions, the alliance will focus on delivering healthcare providers with authorized electronic access to patient medication records and drug monitoring across the continuum of
Approximately one in four patients with poorly controlled idiopathic generalized epilepsy (IGE) having primary generalized tonic-clonic (PGTC) seizures became free from all types of seizures when Keppra (levetiracetam)